TY - JOUR AU - Mizokami, M. AU - Yokosuka, O. AU - Takehara, T. AU - Sakamoto, N. AU - Korenaga, M. AU - Mochizuki, H. PY - 2015 DA - 2015// TI - Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial JO - Lancet Infect Dis VL - 15 UR - https://doi.org/10.1016/S1473-3099(15)70099-X DO - 10.1016/S1473-3099(15)70099-X ID - Mizokami2015 ER - TY - STD TI - The interview form of Ledipasvir Acetonate/Sofosbuvir. https://www.info.pmda.go.jp/go/interview/1/230867_6250107F1026_1_008_1F.pdf. Accessed 30 Jan 2020. UR - https://www.info.pmda.go.jp/go/interview/1/230867_6250107F1026_1_008_1F.pdf ID - ref2 ER - TY - STD TI - The Japan Society of Hepatology. JSH guidelines for the management of hepatitis C virus infection (the 7th edition). https://www.jsh.or.jp/files/uploads/HCV_GL_ver7_02.pdf Accessed 6 Aug 2019. UR - https://www.jsh.or.jp/files/uploads/HCV_GL_ver7_02.pdf ID - ref3 ER - TY - STD TI - The package insert of Interferon Alfa (NAMALWA). https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/400093_6399404A3037_3_21 Accessed 30 Jan 2020. UR - https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/400093_6399404A3037_3_21 ID - ref4 ER - TY - STD TI - The package insert of Simeprevir Sodium. http://www.info.pmda.go.jp/go/pack/6250037M1028_1_13/ Accessed 6 Aug 2019. UR - http://www.info.pmda.go.jp/go/pack/6250037M1028_1_13/ ID - ref5 ER - TY - STD TI - The interview form of Asunaprevir. https://www.info.pmda.go.jp/go/interview/1/670605_6250039M1027_1_009_1F.pdf Accessed 30 Jan 2020. UR - https://www.info.pmda.go.jp/go/interview/1/670605_6250039M1027_1_009_1F.pdf ID - ref6 ER - TY - STD TI - The package insert of Ledipasvir Acetonate/Sofosbuvir. https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/230867_6250107F1026_1_12 Accessed 6 Aug 2019. UR - https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/230867_6250107F1026_1_12 ID - ref7 ER - TY - STD TI - The early post-marketing phase vigilance of Ledipasvir Acetonate/Sofosbuvir. https://www.harvoni.jp/~/media/files/gilead/harvoni/proper/hvn_post_marketing_surveillance_final_report.pdf?la=ja-jp Accessed 6 Aug 2019. UR - https://www.harvoni.jp/~/media/files/gilead/harvoni/proper/hvn_post_marketing_surveillance_final_report.pdf?la=ja-jp ID - ref8 ER - TY - BOOK PY - 2018 DA - 2018// TI - The JRS guidelines for the management of drug-induced lung disease 2nd edition PB - Medical Review Co., Ltd. CY - Tokyo ID - ref9 ER - TY - JOUR AU - Itoh, Y. AU - Sendo, T. AU - Oishi, R. PY - 2006 DA - 2006// TI - Drug-induced lung diseases JO - Folia Pharmacol Jpn VL - 127 UR - https://doi.org/10.1254/fpj.127.425 DO - 10.1254/fpj.127.425 ID - Itoh2006 ER - TY - BOOK AU - Ohtsu, F. AU - Hama, R. PY - 2007 DA - 2007// TI - Adverse drug reactions that are estimated from complaints and symptoms of patients PB - Jiho, Inc. CY - Tokyo ID - Ohtsu2007 ER - TY - JOUR AU - Jantz, M. A. AU - Sahn, S. A. PY - 1999 DA - 1999// TI - Corticosteroids in acute respiratory failure JO - Am J Respir Crit Care Med VL - 160 UR - https://doi.org/10.1164/ajrccm.160.4.9901075 DO - 10.1164/ajrccm.160.4.9901075 ID - Jantz1999 ER -